Identification of p18^INK4c as a Tumor Suppressor Gene in Glioblastoma Multiforme

^{1 1}Lombardi Comprehensive Cancer Center, ²Department of Neurosurgery, Georgetown University School of Medicine, Washington, District of Columbia, and ³Department of Pathology, Duke University School of Medicine, Durham, North Carolina

^* To whom correspondence should be addressed. E-mail: waldmant{at}georgetown.edu.

	Abstract

Genomic alterations leading to aberrant activation of cyclin/cyclin-dependent kinase (cdk) complexes drive the pathogenesis of many common human tumor types. In the case of glioblastoma multiforme (GBM), these alterations are most commonly due to homozygous deletion of p16^INK4a and less commonly due to genomic amplifications of individual genes encoding cyclins or cdks. Here, we describe deletion of the p18^INK4c cdk inhibitor as a novel genetic alteration driving the pathogenesis of GBM. Deletions of p18^INK4c often occurred in tumors also harboring homozygous deletions of p16^INK4a. Expression of p18^INK4c was completely absent in 43% of GBM primary tumors studied by immunohistochemistry. Lentiviral reconstitution of p18^INK4c expression at physiologic levels in p18^INK4c-deficient but not p18^INK4c-proficient GBM cells led to senescence-like G₁ cell cycle arrest. These studies identify p18^INK4c as a GBM tumor suppressor gene, revealing an additional mechanism leading to aberrant activation of cyclin/cdk complexes in this terrible malignancy. [Cancer Res 2008;68(8):2564–9]

Key Words: tumor suppressor gene, glioblastoma multiforme, p18^INK4c, cdk inhibitor, homozygous deletion

This article has been cited by other articles:

				D. A. Solomon, J.-S. Kim, H. W. Ressom, Z. Sibenaller, T. Ryken, W. Jean, D. Bigner, H. Yan, and T. Waldman Sample Type Bias in the Analysis of Cancer Genomes Cancer Res., July 15, 2009; 69(14): 5630 - 5633. [Abstract] [Full Text] [PDF]

				T. Eguchi, H. Itadani, T. Shimomura, N. Kawanishi, H. Hirai, and H. Kotani Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines Mol. Cancer Ther., June 1, 2009; 8(6): 1460 - 1472. [Abstract] [Full Text] [PDF]

				R. Saab, C. Rodriguez-Galindo, K. Matmati, J. E. Rehg, S. H. Baumer, J. D. Khoury, C. Billups, G. Neale, K. J. Helton, and S. X. Skapek p18Ink4c and p53 Act as Tumor Suppressors in Cyclin D1-Driven Primitive Neuroectodermal Tumor Cancer Res., January 15, 2009; 69(2): 440 - 448. [Abstract] [Full Text] [PDF]

				D. A. Solomon, J.-S. Kim, J. C. Cronin, Z. Sibenaller, T. Ryken, S. A. Rosenberg, H. Ressom, W. Jean, D. Bigner, H. Yan, et al. Mutational Inactivation of PTPRD in Glioblastoma Multiforme and Malignant Melanoma Cancer Res., December 15, 2008; 68(24): 10300 - 10306. [Abstract] [Full Text] [PDF]

				D. A. Solomon, J.-S. Kim, W. Jean, and T. Waldman Conspirators in a Capital Crime: Co-deletion of p18INK4c and p16INK4a/p14ARF/p15INK4b in Glioblastoma Multiforme Cancer Res., November 1, 2008; 68(21): 8657 - 8660. [Abstract] [Full Text] [PDF]